Theravance Biopharma, Inc. (TBPH) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $1.00K; Additional Paid in CapitalUSD $1.16B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-76.00K; Retained Earnings (Accumulated Deficit)USD $-870.46M.
- 2026-03-31: Common Stock, Value, IssuedUSD $1.00K; Additional Paid in CapitalUSD $1.16B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-62.00K; Retained Earnings (Accumulated Deficit)USD $-864.56M.
- 2025-12-31: Common Stock, Value, IssuedUSD $1.00K; Additional Paid in CapitalUSD $1.16B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $61.00K; Retained Earnings (Accumulated Deficit)USD $-859.63M.
- 2025-09-30: Common Stock, Value, IssuedUSD $1.00K; Additional Paid in CapitalUSD $1.15B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $32.00K; Retained Earnings (Accumulated Deficit)USD $-920.65M.
Theravance Biopharma, Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Treasury Stock Acquired, Average Cost Per Share USD/shares | Preferred Stock, Value, Issued USD | Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation USD |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.00K | $1.16B | $-76.00K | $-870.46M | $289.70M | $289.70M | 3 month · $5.99M 6 month · $10.49M | (m) | (m) | (m) |
| 2026-03-31 | $1.00K | $1.16B | $-62.00K | $-864.56M | $290.59M | $290.59M | 3 month · $4.50M | (m) | (m) | (m) |
| 2025-12-31 | $1.00K | $1.16B | $61.00K | $-859.63M | $296.72M | $296.72M | 12 month · $18.48M | (m) | (m) | (m) |
| 2025-09-30 | $1.00K | $1.15B | $32.00K | $-920.65M | $232.68M | (m) | 3 month · $4.58M 9 month · $14.00M | (m) | (m) | (m) |
| 2025-06-30 | $1.00K | $1.15B | $-10.00K | $-924.27M | $224.85M | $224.85M | 3 month · $4.54M 6 month · $9.42M | (m) | (m) | (m) |
| 2025-03-31 | $1.00K | $1.15B | (m) | $-979.10M | $165.98M | $165.98M | 3 month · $4.88M | (m) | (m) | (m) |
| 2024-12-31 | (m) | $1.14B | $7.00K | $-965.52M | $175.54M | $175.54M | 12 month · $21.39M | (m) | (m) | (m) |
| 2024-09-30 | (m) | $1.14B | $50.00K | $-950.00M | $185.65M | (m) | 3 month · $4.96M 9 month · $15.57M | (m) | (m) | (m) |
| 2024-06-30 | (m) | $1.13B | $-22.00K | $-937.30M | $193.69M | (m) | 3 month · $5.38M 6 month · $10.60M | (m) | (m) | (m) |
| 2024-03-31 | (m) | $1.13B | $-41.00K | $-920.77M | $204.87M | (m) | 3 month · $5.23M | (m) | (m) | (m) |
| 2024-01-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 1 month · 11.55 17 month · 10.35 | (m) | (m) |
| 2023-12-31 | (m) | $1.12B | $-65.00K | $-909.10M | $213.00M | $213.00M | 12 month · $25.37M | (m) | (m) | (m) |
| 2023-09-30 | $1.00K | $1.15B | $-225.00K | $-900.59M | $246.13M | (m) | 3 month · $6.26M 9 month · $19.55M | (m) | (m) | (m) |
| 2023-06-30 | $1.00K | $1.17B | $-286.00K | $-891.64M | $280.16M | (m) | 3 month · $6.26M 6 month · $13.29M | (m) | (m) | (m) |
| 2023-03-31 | $1.00K | $1.25B | $51.00K | $-876.00M | $370.56M | (m) | 3 month · $7.02M | (m) | (m) | (m) |
| 2022-12-31 | $1.00K | $1.30B | $-15.00K | $-853.91M | $441.80M | (m) | 12 month · $39.73M | (m) | (m) | (m) |
| 2022-09-30 | $1.00K | $1.32B | $-121.00K | $-843.55M | $480.58M | (m) | 3 month · $8.53M 9 month · $32.78M | (m) | (m) | (m) |
| 2022-06-30 | $1.00K | $1.41B | $-45.00K | $-1.76B | $-349.81M | (m) | 3 month · $9.71M 6 month · $24.25M | (m) | (m) | (m) |
| 2022-03-31 | $1.00K | $1.40B | $-28.00K | $-1.75B | $-351.45M | (m) | 3 month · $14.54M | (m) | (m) | (m) |
| 2021-12-31 | $1.00K | $1.39B | (m) | $-1.73B | $-338.57M | (m) | 12 month · $62.06M | (m) | (m) | (m) |
| 2021-09-30 | $1.00K | $1.37B | $14.00K | $-1.69B | $-323.59M | (m) | 3 month · $14.37M 9 month · $45.14M | (m) | (m) | (m) |
| 2021-06-30 | $1.00K | $1.36B | $8.00K | $-1.66B | $-300.37M | (m) | 3 month · $14.94M 6 month · $30.77M | (m) | (m) | (m) |
| 2021-03-31 | $1.00K | $1.23B | $17.00K | $-1.61B | $-373.22M | (m) | 3 month · $15.83M | (m) | (m) | (m) |
| 2020-12-31 | $1.00K | $1.22B | $47.00K | $-1.53B | $-303.75M | (m) | 12 month · $62.98M | (m) | (m) | (m) |
| 2020-09-30 | $1.00K | $1.21B | $122.00K | $-1.47B | $-261.54M | (m) | 3 month · $15.56M 9 month · $47.42M | (m) | $0.00 | (m) |
| 2020-06-30 | $1.00K | $1.19B | $280.00K | $-1.39B | $-202.34M | (m) | 3 month · $16.59M 6 month · $31.86M | (m) | $0.00 | (m) |
| 2020-03-31 | $1.00K | $1.17B | $512.00K | $-1.33B | $-157.94M | (m) | 3 month · $15.28M | (m) | $0.00 | (m) |
| 2019-12-31 | $1.00K | $1.02B | $145.00K | $-1.25B | $-223.84M | (m) | 12 month · $60.45M | (m) | $0.00 | (m) |
| 2019-09-30 | $1.00K | $1.00B | $94.00K | $-1.18B | $-182.81M | (m) | 3 month · $13.02M 9 month · $36.54M | (m) | $0.00 | (m) |
| 2019-06-30 | $1.00K | $987.21M | $129.00K | $-1.12B | $-137.22M | (m) | 3 month · $11.30M 6 month · $23.52M | (m) | $0.00 | (m) |
| 2019-03-31 | $1.00K | $971.51M | $-36.00K | $-1.08B | $-113.25M | (m) | 3 month · $12.22M | (m) | (m) | (m) |
| 2018-12-31 | $1.00K | $960.72M | $-166.00K | $-1.01B | $-51.59M | (m) | 12 month · $51.31M | (m) | $0.00 | (m) |
| 2018-09-30 | $1.00K | $948.84M | $-331.00K | $-961.96M | $-13.45M | (m) | 3 month · $11.73M 9 month · $39.60M | (m) | (m) | (m) |
| 2018-06-30 | $1.00K | $937.44M | $-525.00K | $-902.53M | $34.39M | (m) | 3 month · $13.87M 6 month · $27.87M | (m) | (m) | (m) |
| 2018-03-31 | $1.00K | $925.97M | $-854.00K | $-861.71M | $63.41M | (m) | 3 month · $14.00M | (m) | (m) | (m) |
| 2017-12-31 | $1.00K | $913.65M | $-733.00K | $-797.74M | $115.18M | (m) | 12 month · $49.17M | (m) | (m) | (m) |
| 2017-09-30 | $1.00K | $895.23M | $-292.00K | $-710.82M | $184.12M | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | $1.00K | $885.32M | $-248.00K | $-643.94M | $241.13M | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $1.00K | $871.87M | $-272.00K | $-577.65M | $293.95M | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $1.00K | $862.71M | $-253.00K | $-512.23M | $350.23M | (m) | 12 month · $41.29M | (m) | (m) | (m) |
| 2016-09-30 | (m) | $742.73M | $39.00K | $-444.89M | $297.87M | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | $732.33M | $181.00K | $-410.93M | $321.58M | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | $602.12M | $126.00K | $-363.71M | $238.54M | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | $564.69M | $-70.00K | $-321.56M | $243.06M | (m) | 12 month · $54.17M | (m) | (m) | (m) |
| 2015-09-30 | (m) | $499.23M | $43.00K | $-276.73M | $222.54M | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | $487.06M | $25.00K | $-229.41M | $257.67M | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | $470.89M | $31.00K | $-181.81M | $289.12M | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | $429.21M | $-82.00K | $-139.34M | $289.79M | (m) | 12 month · $43.45M | (m) | (m) | 12 month · $282.00K |
| 2014-09-30 | (m) | $414.88M | $-27.00K | $-75.03M | $339.82M | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | $405.22M | $70.00K | $-20.53M | $384.76M | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) | (m) | $-17.92M | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | $0.00 | $0.00 | $0.00 | $-17.04M | (m) | 12 month · $22.65M | (m) | (m) | (m) |
| 2012-12-31 | (m) | (m) | (m) | (m) | $-6.99M | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | (m) | (m) | (m) | $-140.72M | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |